- KDIGO Guideline for Transplant Recipients
- KDIGO Guideline for CKD-MBD
- KDIGO Guideline for Hep C in CKD
- KDIGO Guideline for Acute Kidney Injury
- KDIGO Guideline for Anemia in CKD
- KDIGO Guideline for Blood Pressure in CKD
- KDIGO Guideline for CKD Classification and Management
- KDIGO Guideline for Glomerulonephritis (GN)
- Participate in the Review Process
- Description of Guideline Development Process
NEWS
KDIGO Announces Anemia Guideline Update
New York, NY (December 18, 2008) –Kidney Disease: Improving Global Outcomes (KDIGO) announced today plans for the development of a new global anemia guideline. The guideline will re-examine the recommendations of the KDOQI guideline on anemia of chronic kidney disease (CKD), published in 2006 and updated in 2007, in light of more recent evidence. Under the leadership of co-chairs Patrick Parfrey, MD, Associate Dean for Clinical Research at the Memorial University of Newfoundland and John McMurray, MD, Professor of Cardiology at the University of Glasgow, an international work group will be convened in early 2010, with the goal of producing an initial draft by the end of the year.
"An updated anemia guideline is considered necessary in light of new study results, particularly the data from “Trial to Reduce Cardiovascular Events with Aranesp Therapy” (TREAT) which was made public in November. The process will be accelerated to publish the guideline in a year rather than two years to ensure that practitioners and patients benefit from new knowledge as soon as possible,” said Kai-Uwe Eckardt, MD, Head of Nephrology and Hypertension at the University of Erlangen-Nuremberg in Germany and Co-Chair of KDIGO.
“The benefits and harms of therapy with erythropoiesis-stimulating agents may be different at different stages of kidney disease, and when certain co-morbidities are present,” said KDIGO’s Co-Chair, Bertram Kasiske, MD, Director of Nephrology, Hennepin County Medical Center. “KDIGO’s rigorous, evidence-based approach, applied by a multidisciplinary group of content experts, will allow us to determine how the new data applies to each affected population.”
A draft of the new guideline is expected to be released for public review in early 2011.
KDIGO Guideline Development Process
KDIGO is a global organization, managed by the National Kidney Foundation (NKF), with the mission to improve patient care and outcomes through the development and implementation of evidence-based clinical practice guidelines.
KDIGO employs an evidence-based approach that is modeled on the guideline development process used in the NKF-Kidney Disease Outcome Quality Initiative (KDOQI™) guidelines. It empowers an independent work group supported by evidence review experts to rigorously examine the published evidence and formulate practice guidelines. Before they are finalized, the draft guidelines undergo a two-stage review process: internal review by the KDIGO Board, followed by open peer review by interested organizations, agencies and individuals worldwide. Reviewer comments are carefully reviewed by the work group, and incorporated as appropriate, before the guidelines are finalized and published in Kidney International.
